Publications

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa and Enterobacterales Causing Pneumonia in Cystic Fibrosis Patients. Lead author: HS Sader, presented at NACFC 2020, October 21-23, Virtual Conference
Poster #315

Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019). by Shortridge D, Pfaller MA, Streit JM and Flamm RK. published in J. Glob. Antimicrob. Resist. 2020; 23: 278

Analysis of a Worldwide Collection of Klebsiella pneumoniae CC258 with Reference to Carbapenemase Production Using the 1928 Core Genome (cg) Multilocus Sequence Type (MLST) Reveals Endemicity and the Global Dissemination of Clones. Lead author Lalitagauri Deshpande. Presented at IDWeek 2020.

Poster #831

Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens. Lead author: Dee Shortridge. Presented at IDWeek 2020.

Poster #1620

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258. Lead Author: Lalitagauri Deshpande. Presented at IDWeek2020.

Poster #1589

Media for colistin susceptibility testing does not improve the detection of Klebsiella pneumoniae isolates carrying MgrB disruption and other mutation driven colistin resistance mechanisms. by Castanheira M, Doyle TB, Carvalhaes CG, Roth BM, Rhomberg PR and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2020; 98 (1): 115077

Activity of Posaconazole and Comparator Antifungal Agents Tested Against Filamentous Fungi. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Poster #1148

Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales-Resistant Subsets to the Aminoglycosides. Primary Author: Helio Sader. Presented at IDWeek 2020.

Poster #1278

Antimicrobial Activity of Dalbavancin against Clinical Isolates of Coagulase-Negative Staphylococci (CoNS) from United States and Europe Stratified by Species. Lead Author: Helio Sader. Presented at IDWeek 2020.

Poster #1449

Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016-2019). Lead Author: Helio Sader. Presented at IDWeek 2020. 

Presentation #37

Plazomicin Activity against Enterobacterales Isolates Producing Extended-Spectrum β-Lactamases (ESBLs), Carbapenemases, and Aminoglycoside-Modifying Enzymes (AMEs) from United States (US) Hospitals. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Poster #1278

Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019. Lead Author: SJ Ryan Arends. Presented at IDWEEK 2020.

Poster #1262

Update on Prevalence of mcr-like Genes Among Enterobacterales in a Global Surveillance Program: Decline in Occurrence of mcr-1.1 and Emergence of mcr-9.1 and mcr-10.1. Lead Author: Lalitagauri Deshpande. Presented at IDWeek 2020.

Presentation Number: 166.

Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Poster #1169

In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanisms. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Presentation #26

Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019. Lead author: LR Duncan, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1595

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258. Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1589

Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infection in European Hospitals (2010-2019). Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #327

Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US. Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster # 1547

Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1463

Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015-2019). Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #333

Antimicrobial Activity of Aztreonam-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019. Lead author: HS Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1261

In Vitro Activity of Omadacycline against 7,000 Bacterial Pathogens from the United States Stratified by Infection Type (2019). Lead author: MD Huband, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1253

Analysis of a Worldwide Collection of Klebsiella pneumoniae CC258 with Reference to Carbapenemase Production Using the 1928 Core Genome (cg) Multilocus Sequence Type (MLST) Reveals Endemicity and the Global Dissemination of Clones. Lead author: LM Deshpande presented at IDWeek2020, October 21-22, Virtual Conference
Poster #831

Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens. Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1620

Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1590

Activity of Ceftazidime-Avibactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals. Lead author: M Castanheira presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1443

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019). Lead author: H Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #2020

Activity of a Series of Investigational Compounds Tested Against Invasive Fungal Isolates. Lead author: PR Rhomberg, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1258

Comparative Epidemiological Analysis of Serratia marcescens using PFGE and Whole Genome Sequence Methods. Lead author: LM Deshpande presented at ID Week 2020, October 21-22, Virtual Conference
Poster #826

Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin. Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1629

Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018–2019) Stratified by Infection Type. Lead author, MD Huband, presented at IDWeek 2020, October 21-22, Virtual Conference.

Poster #1260

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. by Sader HS, Carvalhaes CG, Duncan LR, Flamm RK and Shortridge D. published in J. Antimicrob. Chemother. 2020; 75 (10): 2907-2913

Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam and comparators tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States medical centers in 2016-2018. by Sader HS, Carvalhaes CG, Streit JM, Doyle TB and Castanheira M. published in Microb. Drug Resist. 2021; 27 (3): 342-349

Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and beta-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. by Castanheira M, Doyle TB, Hubler C, Sader HS and Mendes RE. published in Int. J. Antimicrob. Agents. 2020; 56 (1): 106011, 2020

In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017-2018). by Huband MD, Lindley JM, Mendes RE, Fedler KA, Benn VJ, Zhang J, Zhong G, Li L, Zhang M, Tan X and Flamm RK. published in Diag. Microbio. Infect. Dis. 2020; 98 (4): 115191

Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, beta-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019. by Sader HS, Streit JM and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2020; 99 (1): 115195

Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide. by Sader HS, Duncan LR, Arends SJR, Carvalhaes CG and Castanheira M. published in Antimicrob. Agents Chemother.: 2020; 64 (11): e01433

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. by Pfaller MA, Shortridge D, Arends SJR, Duncan LR, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis. 2020; 98 (1): 115101.

Activity of Meropenem-Vaborbactam and Comparator Agents Tested against Enterobacterales Isolates from the United States Analyzed by Site of Infection Lead author: D Shortridge presented at ASM Microbe 2020, June 18-22, Chicago IL, USA
Poster #3804

Antimicrobial activity of ceftolozane-tazobactam and comparators against clinical isolates of Haemophilus influenzae from the United States and Europe. by Sader HS, Carvalhaes CG, Duncan LR and Shortridge D. published in Antimicrob. Agents Chemother. 2020;64 (5): e00211

Activity of plazomicin tested against Enterobacterales isolates collected from U.S. Hospitals in 2016-2017: Effect of different breakpoint criteria on susceptibility rates among aminoglycosides. by Castanheira M, Sader HS, Mendes RE and Jones RN. published in Antimicrob. Agents Chemother. 2020; 64 (5): e02418

In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates. by Huband MD, Mendes RE, Pfaller MA, Lindley JM, Strand GJ, Benn VJ, Zhang J, Li L, Zhang M, Tan X, Liu Q and Flamm RK. published in Antimicrob. Agents Chemother. 2020; 64 (5): e02375

Omadacycline in vitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. by Mendes RE, Huband MD, Streit JM, Castanheira M and Flamm RK. published in Diagn. Microbiol. Infect Dis. 2020; 97 (3):115054.

Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centres (2015-2018). by Sader HS and Jones RN. published in Clin. Microbiol. Infect. 2020; 26 (5): 658-659

Assessment of tedizolid in vitro activity and resistance mechanisms against a collection of Enterococcus spp. causing invasive infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European medical centers, 2016 to 2018. by Carvalhaes CG, Sader HS, Flamm RK, Streit JM and Mendes RE. published in Antimicrob. Agents Chemother. 2020; 64 (4): e00175

Antimicrobial activity of ceftolozane-tazobactam tested against contemporary (2015-2017) P. aeruginosa isolates from a global surveillance program. by Shortridge D, Pfaller MA, Streit JM and Flamm RK. published in J. Glob. Antimicrob. Resist. 2019; 21: 60-64

Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide by Sader HS, Rhomberg PR, Duncan LR, Locher HH, Dale GE and Flamm RK. published in J. Antimicrob. Chemother. 2020; 75 (6): 1518-1524

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016. by Duncan LR, Smith CJ, Flamm RK and Mendes RE. published in J. Glob. Antimicrob. Resist. 2020; 20: 118-123

Bacterial and fungal pathogens isolated from patients with bloodstream infection: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). by Pfaller MA, Carvalhaes CG, Smith CJ, Diekema DJ and Castanheira M. published in Diagn. Microbiol. Infect. Dis. 97 (2): 115016, 2020.